China Botanic Achieves Three Million RMB Sales of New Product

HARBIN, China, Dec. 14, 2010 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that as of fiscal year ending October 31, 2010, the Company's new all-natural anti-depressant and nerve regulation product - Compound Schisandra Tablets ("Schisandra Tablets"), a single plant based medicine, has achieved sales of RMB 3.0 million (or $0.5 million) since its launch in July 2010. The sales are in line with management's original estimates.

Schisandra, also known as magnolia vine, has been clinically proven to provide significant benefits to the functioning and regulation of the central nervous system and respiratory systems. According to the traditional Chinese pharmacopoeia, Schisandra is used as a remedy for many ailments, such as those of the kidneys, insomnia and heart palpitations, and is also widely used as treatment for neurasthenia (a term most commonly used in Traditional Chinese medicine to denote a complex of symptoms characterized by chronic fatigue and weakness, loss of memory, and generalized aches and pains).

"Compound Schisandra Tablets complements our existing anti-depressant and nerve regulation Ginseng based product series, and strengthens China Botanic's goal to be the world's leading company specializing in plant-based medicine," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic.. "We are pleased with the initial strong sales and market acceptance of our Schisandra Tablets, which are in line with our sales forecast. This reflects well on our thorough market research and sales and marketing strategy. We will continue to develop market oriented all-natural plant based products to capitalize on the attractive market opportunities."

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.

China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China.  All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to expand its Schisandra Tablets sales, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.